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Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia
associated with cancer chemotherapy
JA Glaspy*,1, JS Jadeja2, G Justice3, J Kessler4, D Richards5, L Schwartzberg6, NS Tchekmedyian7,
S Armstrong8, J O’Byrne8, G Rossi8 and AB Colowick8
1200 UCLA Medical Plaza, Suite 202, Los Angeles, California, CA 90095-6956, USA; 2Hematology-Oncology Associates of Jacksonville, 5742 Booth Road,
Jacksonville, Florida, USA; 3Pacific Coast Hematology Oncology Medical Group, 11190 Warner Avenue, Suite 300, Fountain Valley, California, USA;
4Virginia Oncology Associates, 895 Middle Ground Boulevard, Newport News, Virginia, USA; 5Tyler Cancer Center, 910 E Houston, Tyler, Texas, USA;
6The West Clinic, 100 N Humphries Blvd, Suite 100, Memphis, Tennessee, USA; 7Pacific Shores Medical Group, 1043 Elm Avenue, Suite 104, Long
Beach, California, USA; 8Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, CA 91320, USA
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to
8.0 m.c.g. kg71 wk71 or to a control group receiving epoetin alfa at an initial dose of 150 U kg71 three times weekly. In
part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg71 every 2 weeks or epoetin alfa, initial dose 40 000 U wk71.
Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy
was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of
darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any
adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased
the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of
darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased
from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin
levels in patients with cancer receiving chemotherapy.
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Patients with cancer are frequently anaemic, with contributing
factors including chemotherapy and the anaemia of chronic
disease, with endogenous erythropoietin deficiency, relative
erythropoietin resistance, and shortened red cell survival (Miller
et al, 1990). It has been recognised that, even in the setting of
mild and moderate degrees of anaemia, anaemia is an important
contributing factor to the fatigue experienced by cancer patients
(Vogelzang et al, 1997; Glaspy et al, 1997; Demetri et al, 1998;
Gabrilove et al, 2001).
Recombinant human erythropoietin (rHuEPO) is effective for
treating anaemia in patients receiving chemotherapy. Randomised
trials demonstrated that increasing haemoglobin concentrations
were associated with approximately a 50% reduction in adminis-
tered transfusions (Cascinu et al, 1994; Henry and Abels, 1994).
Large, open-label studies suggest that therapy with rHuEPO is
associated with an improvement in energy level, ability to do daily
activities, and overall quality of life (Demetri et al, 1998; Glaspy et
al, 1997; Gabrilove et al, 2001). This improvement in the quality of
life and fatigue level associated with rHuEPO treatment has been
confirmed in a randomised, placebo-controlled clinical trial (Little-
wood et al, 2001). The recognition that anaemia is an important
factor in the quality of life of cancer patients has led to an increase
in the use of rHuEPO in this setting (Gabrilove et al, 2001).
Despite this success, the most effective dose and schedule of
rHu-EPO to relieve fatigue as efficiently as possible have not been
established.
Darbepoetin alfa is the recombinant product of a gene produced
through site-directed mutagenesis of the erythropoietin gene that
increases the glycosylation of the protein. Darbepoetin alfa binds
to the erythropoietin receptor with the same fidelity and stimulates
erythropoiesis by the same mechanism as endogenous erythropoie-
tin and rHuEPO (Egrie et al, 1997). Despite darbepoetin alfa’s
reduced affinity for the erythropoietin receptor, it has increased
potency due to its extended serum residence time (Egrie et al,
1997).
This increased in vivo potency has been confirmed in clinical
trials in patients with renal failure (Macdougall et al, 1999). In this
setting, darbepoetin alfa has a three-fold longer terminal half-life
than rHuEPO (25.3 h vs 8.5 h) and can be administered less
frequently with the same efficacy as rHuEPO.
In the cancer setting, the dosing recommendation for rHuEPO
in the package insert (US) is 150 U kg71 administered three times
weekly, or approximately 10 000 U three times weekly. A large,
phase 4 study has shown that increasing the label-recommended
weekly dose by 33% to 40 000 U wk71 administered as a single
injection produces a haematologic response after 16 weeks of ther-
apy in 49% of patients (Gabrilove et al, 2001). The response rate
increased to 68% when the dose for patients with an inadequate
response after 4 weeks was increased to 60 000 U wk71. These
response rates appear to be comparable to three times weekly
dosing schedules using the lower overall rHuEPO doses (Demetri
et al, 1998).
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Clinical trials of darbepoetin alfa during cancer chemotherapy
aimed at fully elucidating the dose – response relationships and
optimising scheduling are underway. Initial data demonstrated that
darbepoetin alfa can be administered as infrequently as once every
3 weeks (Kotasek et al, 2000). We report the results of a large,
randomised, active-controlled, dose-finding study of darbepoetin
alfa given subcutaneously every 1 or 2 weeks during cancer
chemotherapy. Preliminary safety and efficacy results of the first
weekly dose cohorts have been previously reported (Glaspy et al,
2001).
The purpose of this study was to assess the safety of darbepoetin
alfa in patients receiving cancer chemotherapy, to assess the feasi-
bility of administering darbepoetin alfa every week and every 2
weeks, and to characterise the dose – response relationships for
darbepoetin alfa when given every week or every 2 weeks.
PATIENTS AND METHODS
Patients
The protocol was approved by the institutional review boards of
participating centres; all patients gave written informed consent
before any study-related procedures were done. Eligible patients
were at least 18 years of age, had solid tumours, and were sched-
uled to receive cyclic chemotherapy for at least 12 weeks after
enrolment. Patients were required to be anaemic (haemoglobin
411.0 g dl71) and to have an Eastern Cooperative Oncology
Group performance status of 0 to 2 and adequate renal function
(serum creatinine 52 mg dl71). Patients with anaemia due to
iron, folate, or B12 deficiency, haemolysis, bleeding, or active infec-
tion, and those with transferrin saturation 515% or serum ferritin
concentration 510 ng ml71, were excluded. Patients were
excluded if they had received more than two red blood cell transfu-
sions within 4 weeks or any red cell transfusions within 16 days of
randomisation, had received epoetin alfa therapy within 8 weeks,
or had known central nervous system metastases.
Study drugs
Patients were randomised to receive darbepoetin alfa
(ARANESPTM, Amgen Inc., Thousand Oaks, CA, USA) or epoetin
alfa (Procrit1, Ortho Biotech, Raritan, NJ, USA), the latter used in
a fashion consistent with either the US package insert (part A) or
clinical practice (part B), to provide a safety comparator for darbe-
poetin alfa in a patient population in which a high incidence of
adverse events due to chemotherapy or malignancy was expected.
In keeping with other studies with erythropoietic agents, a wide
variety of chemotherapies, regimens, and schedules were used in
the study.
Study design
This was a phase 1/2, multicentre, randomised, active-controlled,
open-label study in which anaemic patients with solid tumours
who were receiving multicycle chemotherapy received 12 weeks
of subcutaneous therapy with darbepoetin alfa or epoetin alfa
(Figure 1). Part A was a sequential dose-finding study in which
patients were randomised in a 4 : 1 ratio to receive either once-
weekly doses of darbepoetin alfa (0.5, 1.0, 1.5, 2.25, 4.5, 6.0 or
8.0 m.c.g. kg71) or epoetin alfa 150 U kg71 three times weekly.
In part A, dose-escalation decisions were determined by a data
monitoring committee, based on specific safety criteria being satis-
fied. The exact size of each cohort was not prespecified, although
a target size of 30 patients for each dose cohort was defined.
Because of recommendations made by the data monitoring
committee, additional patients were enrolled at some dose cohorts
and three additional dose cohorts were included. Consequently,
some variation in the actual size of the dose cohort exists. Part
B was a parallel dose-finding and dose-schedule study in which
patients were randomised in a 1 : 1 : 1 : 1 ratio to receive one dose
of darbepoetin alfa (3.0, 5.0, 7.0 or 9.0 m.c.g. kg71) once every 2
weeks or epoetin alfa 40 000 U wk71. The randomisation allowed
for approximately 30 patients to receive study drug per dose
group. Study drug was administered on the first day of
chemotherapy.
The doses of darbepoetin alfa were not increased to facilitate
characterisation of the dose-response relationship. The study proto-
col allowed the dose of epoetin alfa to be increased for patients in
whom an inadequate response (i.e., 51.0 g dl71 increase in
haemoglobin) was observed. In part A, the dose could be increased
to 300 U kg71 three times weekly at week 8. In part B, the dose
could be increased to 60 000 U wk71 at week 6. Because dose
increases were allowed with epoetin alfa, the ability to directly
compare the efficacy of an individual dose of darbepoetin alfa with
epoetin alfa is confounded, although some descriptive comparisons
can be made.
Safety endpoints
The primary objective of this study was to assess the safety of
darbepoetin alfa during cancer chemotherapy. All reported adverse
events were grouped according to body system affected by
preferred term according to a modified World Health Organisation
adverse reaction term (WHOART) dictionary. In addition, changes
in blood pressure, changes in haemoglobin concentrations, and the
formation of antibodies to darbepoetin alfa were examined.
Efficacy endpoints
The efficacy of darbepoetin alfa was assessed utilizing several
endpoints related to haemoglobin concentration including
haemoglobin response (52.0 g dl71 increase over baseline in
the absence of a red cell transfusion in the preceding 28 days);
time to haemoglobin response; change in haemoglobin from
baseline at week 4 and week 13; and haematopoietic response
(haemoglobin value 412.0 g dl71 or a 52.0 g dl71 increase in
haemoglobin over baseline value in the absence of a red cell
transfusion in the past 28 days) (Gabrilove et al, 2001). An
exploratory analysis was done to compare the efficacy of a simi-
lar weekly exposure to darbepoetin alfa when administration was
every week or every 2 weeks.
The effect of changes in haemoglobin concentration on
fatigue was studied using the Functional Assessment of Cancer
Therapy – Fatigue (FACT-F) scale.
Statistical analysis
Analyses were conducted using an intent-to-treat set that
included all patients who received at least one dose of study
drug. Baseline demographic and clinical characteristics were
summarised by the mean for continuous measures and number
for categorical measures. Changes in haemoglobin endpoints were
summarised as a mean with 95% confidence limits. Time to
haemoglobin response was summarised by Kaplan – Meier curves.
The proportion of patients achieving haematopoietic response
was estimated by subtracting the Kaplan – Meier estimate of the
survivor function at the time of the last observed haematopoietic
response from 1, with 95% confidence limits calculated by using
Greenwood’s estimate of the variance. FACT-F scale scores were
summarised using medians with 95% confidence limits for all
darbepoetin alfa and all epoetin alfa patients combined for the
following haemoglobin categories: 50 g dl71, 0 to
51.0 g dl71 1 to 52.0 g dl71, 2.0 to 53.0 g dl71, and
53.0 g dl71.
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RESULTS
Patient demographics and disposition
At least one dose of study drug was received by 269 patients (216
darbepoetin alfa, 53 epoetin alfa) in part A and 160 patients (128
darbepoetin alfa, 32 epoetin alfa) in part B. Baseline characteristics
of patients were well balanced (Table 1). The proportion of
patients completing 3 months of protocol treatment was similar
for darbepoetin alfa and epoetin alfa (62 vs 57%, and 58 vs
63%, for darbepoetin alfa vs epoetin alfa in parts A and B, respec-
tively). The reasons for early discontinuation of study drug
treatment were similar for darbepoetin alfa and epoetin alfa
patients and included death (5 vs 8%), disease progression (3 vs
2%), consent withdrawn (7 vs 9%), and chemotherapy discontin-
ued or delayed (8 vs 9%), respectively. On average, the
darbepoetin alfa cohorts received the intended dose with the
exception of the 2.25 m.c.g. kg71 wk71 cohort in part A, in
which the mean dose received was 2.05 m.c.g. kg71 wk71 due
to protocol-specified dose reductions for rapid haemoglobin
increases. The protocol was subsequently amended to remove
these dose reduction criteria.
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Figure 1 Study design and treatment schema. See text for information concerning dose adjustments for patients receiving epoetin alfa. In part A (A),
darbepoetin alfa was administered once every week; in part B (B), it was administered once every 2 weeks.
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Safety
The most frequently reported adverse events were those expected in
a population of cancer chemotherapy patients and occurred at a
similar frequency within the darbepoetin alfa and epoetin alfa
groups (Figure 2). For all events other than fatigue, the 95% confi-
dence limits of the odds ratio include 1, suggesting no difference
between darbepoetin alfa and epoetin alfa. No apparent relationship
was noted between an increasing rate of any adverse event and the
dose of darbepoetin alfa. The rates of serious adverse events and
adverse events of grade 3 or greater were similar in patients receiv-
ing darbepoetin alfa and in those receiving epoetin alfa.
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Table 1 Baseline demographic and clinical characteristics for all patients enrolled in the clinical
trial (intent-to-treat population). Part A, darbepoetin alfa was administered once every week; Part
B, it was administered once every 2 weeks
Part A Part B
Darbepoetin alfa Epoetin alfa Darbepoetin alfa Epoetin alfa
n=216 n=53 n=128 n=32
Age (years)
Mean (s.d.) 61.9 (11.9) 57.8 (14.5) 64.3 (12.0) 63.9 (12.3)
Sex (n/%)
Men 70 (32%) 15 (28%) 46 (36%) 10 (31%)
Women 146 (68%) 38 (72%) 82 (64%) 22 (69%)
Primary disease (n/%)
Breast 64 (30%) 15 (28%) 29 (23%) 6 (19%)
Gastrointestinal 41 (19%) 12 (23%) 36 (28%) 13 (41%)
Lung 40 (19%) 11 (21%) 31 (24%) 7 (21%)
Other 71 (32%) 15 (28%) 32 (25%) 6 (19%)
ECOG status (n/%)
0 68 (31%) 12 (23%) 38 (30%) 8 (25%)
1 127 (59%) 34 (64%) 78 (61%) 19 (59%)
2 19 (9%) 7 (13%) 9 (7%) 4 (13%)
42/unknown 2 (1%) 0 (0%) 3 (2%) 1 (3%)
Haemoglobin (g dl71)
Mean (s.d.) 9.91 (0.94) 10.02 (0.88) 9.82 (0.95) 9.73 (1.17)
Endogen. EPO (mU ml71)
Mean (s.d.) 58.04 (138.33) 45.29 (38.18) 55.11 (48.85) 24.23 (12.98)
Ferritin (m.c.g. l71)
Mean (s.d.) 502.3 (514.4) 540.6 (593.3) 541.0 (707.5) 481.8 (484.3)
ECOG=Eastern Cooperative Oncology Group; s.d.=standard deviation.
Fatigue
Nausea
Diarrhea
Vomiting
Dyspnea
Fever
Pain abdominal
Anorexia
Pain back
Arthralgia
Pain limb
Constipation
Edema peripheral
Pain chest (non-cardiac)
Asthenia
Pain
Insomnia
Depression
Dizziness
Cough
Headache
Myalgia
Pain skeletal
Infection upper respiratory
Increased incidence
on darbepoetin alfa
Decreased incidence
on darbepoetin alfa
0.001 0.01 0.1 1 10 100 1000
Treatment difference (Darbepoetin alfa/Epoetin alfa)
Figure 2 Comparison of adverse events that occurred with 510% incidence in patients receiving darbepoetin alfa and epoetin alfa. Bars represent 95%
confidence limits of the odds ratio.
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No relationship was noted between the changes in haemoglobin
and changes in blood pressure or between the rate of change in
haemoglobin and any specific adverse event, including cardiovascu-
lar and thrombotic events.
The effect of discontinuing darbepoetin alfa on the trajectory of
the rise in haemoglobin was assessed in patients who met prespe-
cified haemoglobin thresholds (14.0 g dl71 for women and
15.0 g dl71 for men). A plateau of the haemoglobin concentration
was observed within 1 to 2 weeks, followed by a gradual decline
until the study drug was reinstated per protocol when the patient’s
haemoglobin reached 13.0 g dl71. Two women (one darbepoetin
alfa and one epoetin alfa) exceeded the normal range of haemoglo-
bin during the study without any clinical sequelae. Despite the
longer half-life of darbepoetin alfa, the rate of decline was compar-
able to that of epoetin alfa and did not appear to be dose
dependent.
Patients’ sera were screened at regular intervals using a radioim-
munoprecipitation assay to detect antibodies to darbepoetin alfa.
No serum reactivity was observed within 1200 assays done on
samples from 205 patients exposed to 1800 patient-weeks of darbe-
poetin alfa. In addition, no clinical sequelae suggestive of the
formation of neutralising antibodies were observed.
Efficacy endpoints
The cumulative proportion of patients achieving a haemoglobin
response is shown in Figure 3. A dose – response relationship was
evident for patients receiving darbepoetin alfa once every week
up to doses of 4.5 m.c.g. kg71. Higher doses did not appreciably
increase efficacy for a given dose cohort. The dose response was
evident not only for the overall proportion of patients achieving
a response but also for rapidity of the response. At 4.5 m.c.g. kg71,
the median time to response was 7 weeks (confidence limits, 6 to
10 weeks) compared with 10 weeks (confidence limits, 8 weeks to
unestimable) for patients receiving 2.25 m.c.g. kg71 or those
receiving epoetin alfa. A dose response was not as evident for the
doses administered once every 2 weeks, which all produced haema-
tologic responses in more than 60% of the patients and which
suggested a dose/time-to-response relationship.
The mean change in haemoglobin associated with the various
doses and schedules of darbepoetin alfa was examined (Figure 4).
In part A, a trend towards greater increases in haemoglobin with
higher doses of darbepoetin alfa was observed: the rise was
1.4 g dl71 in the 0.5 m.c.g. kg71 wk71 cohort compared with a
rise of 2.75 g dl71 in the 8.0 m.c.g. kg71 wk71 cohort. Similarly,
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in part B, higher doses of darbepoetin alfa were generally associated
with a greater change in haemoglobin compared with lower doses.
It is clinically relevant to consider earlier time points than week
13 (end of treatment) for assessing the impact of therapy on
haemoglobin concentration. In part A, a trend towards greater
increases in haemoglobin with higher doses of darbepoetin alfa
was observed (Figure 4). In part B, patients receiving darbepoetin
alfa doses of 3.0, 5.0 and 7.0 m.c.g. kg71 every 2 weeks had similar
mean increases in haemoglobin at week 4 (0.61, 0.58 and
0.61 g dl71, respectively), whereas patients receiving darbepoetin
alfa at 9.0 m.c.g. kg71 every 2 weeks had a larger mean increase
of 1.23 g dl71.
We assessed the relative efficiency of the same overall dose of
darbepoetin alfa when administration was weekly compared with
every 2 weeks (Figure 5). For each of the dosing couplets for which
such a comparison is possible, the proportion of patients achieving
a haematopoietic response was similar regardless of dosing interval.
This finding suggests a linear relationship for dose requirements as
the interval of dosing is increased from every week to every 2
weeks.
Of the 429 patients in the intent-to-treat analysis, fatigue score
data were available for 408 (329 darbepoetin alfa, 79 epoetin alfa).
Due to the small size of each dose cohort, the impact on fatigue,
using changes in FACT-F scores, was analysed by change in haemo-
globin category rather than by dose group/schedule of
administration. The effect of a given change in haemoglobin
concentration on FACT-F scores was similar between darbepoetin
alfa- and epoetin alfa-treated patients (Table 2).
DISCUSSION
The recognition that fatigue is a major determinant of the func-
tional status and quality of life of cancer patients and that mild
degrees of anaemia contribute to this fatigue, coupled with the
demonstration that increasing haemoglobin concentrations can
reduce these fatigue levels, has led to an increase in the use of
rHuEPO in this setting. Most studies have used three times
weekly doses of 150 U kg71, with a dose increase to
300 U kg71 in non-responders (Cascinu et al, 1994; Henry and
Abels, 1994). This schedule remains indicated for rHuEPO,
although common practice in the US is to administer rHuEPO
once a week. The dosing and scheduling of rHuEPO during
cancer chemotherapy are increasingly important issues, as they
affect the proportion of patients who benefit and the cost-utility
of this therapy. It is important that new erythropoietic agents
be developed with attention to optimised dose and schedule. This
paper is the final report of a randomised, active-controlled, dose-
finding trial of darbepoetin alfa therapy given every week or every
2 weeks during cancer chemotherapy.
The primary endpoint of this study was the safety of darbepoe-
tin alfa. The adverse event profile observed with darbepoetin alfa
was similar to that observed with epoetin alfa, dominated by those
events expected in this patient population. Serious adverse events
were frequent but were related to the cancer or the chemotherapy.
Fatigue was reported as an adverse event more frequently in
patients receiving darbepoetin alfa than in those receiving epoetin
alfa. Because the darbepoetin group included patients treated at
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Figure 3 Cumulative proportion of patients achieving a haemoglobin response (defined as a 52.0 g dl71 increase over baseline). Patients who did not
manifest a haemoglobin response to epoetin alfa had their dose increased at week 8 in part A and week 6 in part B. In part A (A), darbepoetin alfa was
administered once every week; in part B (B), it was administered once every 2 weeks.
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relatively low doses in whom a suboptimal haemoglobin response
was observed, it is likely that the increased fatigue reported was
related to excess anaemia. Using the validated FACT-F instrument,
we observed that for a given improvement in haemoglobin, an
equivalent decrease in fatigue is observed with both darbepoetin
alfa and epoetin alfa.
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Figure 4 Mean change from baseline in haemoglobin at weeks 4 and 13. In part A, darbepoetin alfa was administered once every week; in part B, it was
administered once every 2 weeks. Bars represent standard error of the mean.
Table 2 Median change in fatigue as self-reported using the FACT-F scale
Change in
Patient number (%)
Change in FACT-F score
(95% confidence limit)
haemoglobin (g dl71) Darbepoetin alfa Epoetin alfa Darbepoetin alfa Epoetin alfa
50 62 (19%) 14 (18%) 71 (75, 2) 0.5 (73, 11)
0 to 51 73 (22%) 15 (19%) 0 (71, 1) 3 (0, 18)
1 to 52 66 (20%) 14 (18%) 2 (71, 8) 71 (76, 8)
2 to 53 55 (17%) 20 (25%) 4 (1, 10) 5.5 (75, 11)
53 73 (22%) 16 (20%) 5 (2, 8) 4.5 (1, 16)
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In studies of patients with renal failure undergoing dialysis,
rapid changes in haemoglobin associated with rHuEPO therapy
may be associated with an increased incidence of hypertension
and thrombosis of dialysis shunts. These phenomena are thought
to be related to increasing red cell mass in the absence of
normal-volume homeostasis. These complications have not been
observed in the setting of cancer chemotherapy (Glaspy et al,
1997; Demetri et al, 1998; Gabrilove et al, 2001; Littlewood et al,
2001). In our study, no relationship between the rapidity of
haemoglobin response and any adverse event was observed, consis-
tent with the clinical experience with rHuEPO in cancer patients.
Finally, although darbepoetin alfa is a longer-acting erythropoietic
agent than epoetin alfa, only two patients who had haemoglobin
414 or 15 g dl71 had haemoglobin concentrations that continued
to increase to above normal range when darbepoetin alfa therapy
was discontinued; no clinical sequelae were associated with these
increases. Darbepoetin alfa appears to be safe and well tolerated
in the setting of cancer chemotherapy.
Recently, a number of cases of pure red cell aplasia associated
with antibodies to one type of rHuEPO (Eprex) have been reported
in patients with chronic renal failure (Casadevall et al, 2002). These
cases do not appear to be associated with other preparations of
epoetin alfa (Epogen, Procrit). The neutralizing antibodies bound
only to the protein moiety and not to the carbohydrate moiety
of the rHuEPO and crossreacted with all commercially available
recombinant erythropoietic products, including darbepoetin alfa.
Darbepoetin alfa is a modified erythropoietin molecule with five
amino acid substitutions and more sialic acid than native erythro-
poietin or rHuEPO. Because the amino-acid substitutions are at, or
proximal to, the carbohydrate addition site, it is likely that these
new epitopes are shielded from immune surveillance (Egrie and
Browne, 2001). The type of carbohydrate moiety present on
darbepoetin alfa (six chains) and rHuEPO (four chains) are iden-
tical. Darbepoetin alfa has been administered for up to 2 years
without serum immunoreactivity being observed in patients with
renal failure who were undergoing dialysis (Macdougall, 2001).
In our study, no serum immunoreactivity was observed within
1200 assays done on samples from 205 patients exposed to darbe-
poetin alfa for 1800 patient-weeks. These observations are
consistent with those in other studies of darbepoetin alfa adminis-
tered to cancer patients (Kotasek et al, 2000; Heatherington et al,
2001; Smith et al, 2001). These clinical data are consistent with
the preclinical prediction that anti-darbepoetin alfa antibody
responses would not occur.
An objective of this study was to explore the dose-response rela-
tionship for darbepoetin alfa. Our data demonstrate that when
darbepoetin alfa is administered every week, the proportion of
patients who demonstrate a hematologic response increases as the
dose is increased up to 4.5 m.c.g. kg71 wk71. At that dose,
approximately 76% (95% confidence limit: 59 to 94%) of the
patients met criteria for a haemoglobin response, and 80% (95%
confidence limit: 70 to 98%) had a haematopoietic response (either
normalised or responded). When darbepoetin alfa was adminis-
tered every 2 weeks, a similar relationship between the
proportion of responders and the dose administered was observed
up to a dose of 9 m.c.g. kg71 every 2 weeks. At that dose, 67%
(95% confidence limit: 48 to 85%) of patients were responders,
and 71% (95% confidence limit: 53 to 89%) either normalised
or responded. Because intrapatient dose escalation was not
permitted in this study for patients receiving darbepoetin alfa, these
data do not speak to whether higher doses may allow for an indi-
vidual patient to respond to darbepoetin alfa. Further studies are
warranted in which patients who do not exhibit an early haemoglo-
bin response are allowed to increase their dose of darbepoetin alfa
to define the effect of dose escalation.
Similar trends towards increasing efficacy with increasing doses
of darbepoetin alfa were observed for other efficacy endpoints,
including the mean change in haemoglobin after 4 weeks and
at the end of study (typically week 13). Importantly, a relation-
ship between dose and rapidity of response is apparent, with
higher doses of darbepoetin alfa achieving faster responses than
lower doses or epoetin alfa. The median time to response for
patients receiving 4.5 m.c.g. kg71 wk71 was 7 weeks (confidence
limit: 6 to 10) compared with 10 weeks (confidence limit: 8 to
unestimable) observed for patients receiving 2.25 m.c.g. kg71
darbepoetin alfa every week or epoetin alfa 150 U kg71 adminis-
tered three times weekly, including the dose increase for
nonresponding patients. This rapid response should translate into
more rapid relief of fatigue and improvement in functional
status.
Another observation is that the results achieved with darbepoe-
tin alfa administered every week are similar to those achieved with
twice the dose administered every 2 weeks. This finding may
contrast with the results with epoetin alfa, where it is possible that
a 33% increase in the total dose three times weekly is necessary for
once-every-week dosing (Gabrilove et al, 2001). Darbepoetin alfa
may permit more flexible scheduling of erythropoietic therapy
without compromising cost-effectiveness.
This study has limitations. Because it was designed to be a
dose-finding study, a direct comparison of the clinical effects of
epoetin alfa and a given dose or schedule of darbepoetin alfa is
not feasible. We administered darbepoetin alfa at the same maxi-
mum dose within each cohort without allowing for dose increases
in those patients who did not respond early to therapy. Epoetin
alfa dose escalations were permitted for patients in whom an
inadequate early response was observed. Thus, any comparison
of efficacy between the two drugs is likely to underestimate the
full potential of a given starting dose of darbepoetin alfa. Second,
at least with doses of up to 8 m.c.g. kg71 wk71, we have not
eliminated the important clinical problem of non-responders to
erythropoietic therapy. With the data available, we cannot deter-
mine the proportion of patients who would remain
unresponsive if higher doses of darbepoetin alfa were used. Third,
our entry criteria permitted participation by patients who may
have had marginal or deficient iron reserves that may have
compromised their response to epoetin alfa or darbepoetin alfa.
Although these entry criteria were similar to those used in other
studies of erythropoietic agents for cancer patients (Glaspy et al,
1997; Demetri et al, 1998; Gabrilove et al, 2001), it is possible that
higher response rates or lower epoetin alfa or darbepoetin alfa
doses would have been observed if more strict entry criteria had
been used or if more aggressive iron supplementation had been
mandated.
We conclude that darbepoetin alfa therapy is safe when adminis-
tered to cancer patients receiving chemotherapy. An apparent
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relationship appears to exist between darbepoetin alfa dose and
both the magnitude and rapidity of haematologic response. The
overall dose of darbepoetin alfa required to produce a given mean
increase in haemoglobin concentration does not increase when the
dosing interval is increased from 1 to 2 weeks, allowing for greater
flexibility when managing a patient’s anaemia without adversely
affecting the cost of therapy for the benefits of less-frequent dosing.
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